Virios Therapeutics Inc
Change company Symbol lookup
Select an option...
VIRI Virios Therapeutics Inc
TCBS Texas Community Bancshares Inc
UPC Universe Pharmaceuticals Inc
MHH Mastech Digital Inc
GCTK GlucoTrack Inc
KODK Eastman Kodak Co
FYBR Frontier Communications Parent Inc
TPNEF Cub Energy Inc
ECC Eagle Point Credit Co LLC
CPHI China Pharma Holdings Inc
Go

Health Care : Biotechnology |
Company profile

Virios Therapeutics, Inc., formerly Virios Therapeutics, LLC., is a development-stage biotechnology company focused on advancing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM). Its lead development candidate is IMC-1, which is a fixed dose combination of famciclovir and celecoxib. IMC-1 represents a combination antiviral therapy designed to synergistically suppress Herpes Simplex Virus-1 (HSV-1) activation and replication. Its HSV-1 root cause of chronic illnesses such as FM, irritable bowel disease (IBS), chronic fatigue syndrome and functional somatic syndrome. The Company is developing its initial candidate, IMC-1, for people who are suffering from fibromyalgia.

Closing Price
$6.15
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
60,939
0

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amazon.com, Inc. (AMZN)

11:00 am ET July 1, 2022 (BusinessWire) Print

The Law Offices of Frank R. Cruz reminds investors of the upcoming July 5, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Amazon.com, Inc. ("Amazon" or the "Company") (NASDAQ: AMZN) stock between February 1, 2019 and April 28, 2022, inclusive (the "Class Period").

If you are a shareholder who suffered a loss, click here to participate.

In June 2019, the U.S. House Committee on the Judiciary initiated a bipartisan investigation into the state of competition online, which examined the business practices and market dominance of Amazon, Facebook, Google, and Apple.

On March 9, 2022, media outlets reported that the House Judiciary Committee had requested the U.S. Department of Justice ("DOJ") to open a criminal investigation into Amazon and certain of its executives for allegedly lying to Congress during the course of its investigation.

On April 6, 2022, The Wall Street Journal reported that the U.S. Securities and Exchange Commission is investigating how Amazon handled disclosures on employees' use of third party sellers' data to boost its own private-label business.

On this news, the Company's stock price fell $105.98, or 3.2%, to close at $3,175.12 per share on April 6, 2022, thereby injuring investors.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Amazon engaged in anticompetitive conduct in its private-label business practices, including giving Amazon products preference over those of its competitors and using third-party sellers' non-public data to compete with them; (2) the foregoing exposed Amazon to a heightened risk of regulatory scrutiny and/or enforcement actions; (3) Amazon's revenues derived from its private-label business were in part the product of impermissible conduct and thus unsustainable; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased or otherwise acquired Amazon stock during the Class Period, you may move the Court no later than July 5, 2022 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220701005080/en/

SOURCE: The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com 
www.frankcruzlaw.com
comtex tracking

COMTEX_409534043/1006/2022-07-01T11:00:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.